Clarivate(CLVT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $617 million, bringing the full year total to $2.455 billion, with changes driven entirely by inorganic factors due to business disposals [18] - Full year net income improved by $436 million compared to the previous year, primarily due to the absence of non-cash impairment charges and lower income tax and interest expenses [18] - Adjusted diluted EPS increased by $0.02 sequentially to $0.20 [18] - Operating cash flow for Q4 was $160 million, reflecting a $19 million improvement year-over-year [19] - Free cash flow for the full year reached $365 million, representing approximately 2% growth over the prior year [22] Business Line Data and Key Metrics Changes - The Academia and Government segment achieved 2% organic ACV growth, with 93% of revenue now coming from proprietary solutions [12] - The Intellectual Property business saw a 270 basis points year-over-year improvement in annuities revenue, indicating stronger execution [15] - Life Sciences & Healthcare reported significant adoption of AI solutions, with 11,000 global active users leveraging AI research assistants [15] Market Data and Key Metrics Changes - The company expects organic annual contract value growth of 2%-3% for 2026, an acceleration from previous years [16] - Recurring organic revenue is targeted to grow by 1%-2% in 2026, an improvement of nearly 100 basis points compared to the previous year [16] - The company anticipates a modest foreign exchange translation benefit of $10 million for the year [26] Company Strategy and Development Direction - The company is focusing on selling its Life Sciences & Healthcare business to enhance value creation and strengthen its balance sheet [6][12] - The strategy emphasizes AI as an amplifier of existing business models rather than a disruption, with 97% of revenue derived from proprietary assets [7][8] - The company aims to optimize its business model and improve sales execution, with a focus on innovation and product development [11][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve 10% free cash flow growth in 2026, supported by strong cash generation and stable revenue retention rates [5] - The management acknowledged market concerns regarding AI disruption but emphasized the proprietary nature of their business as a competitive advantage [7] - The outlook for the Intellectual Property segment is increasingly positive, with expectations of returning to organic revenue growth [16] Other Important Information - The company has launched a process to sell its Life Sciences & Healthcare business, which is expected to focus operational execution on A&G and IP segments [6][12] - The company has introduced 12 major products and AI-powered features in 2025, strengthening its market position [11] Q&A Session Summary Question: Can you talk about your monetization model for your subscriptions and for the new AI products? - The company continues to use AI to protect and grow its subscription revenue, with upsell opportunities for existing products and a shift towards more subscription-based models [34][36] Question: Can you explain the 97% of revenue coming from proprietary data? - The company clarified that 97% of its business derives from proprietary data, with a significant portion coming from information services and enterprise software [42][43] Question: What were the key considerations for initiating a sale process for the Life Sciences and Healthcare business? - The decision was based on the goal of creating shareholder value and focusing on operational execution across A&G and IP segments [50][51] Question: What will it take to return the IP segment to organic revenue growth? - Management highlighted the importance of product innovation and market recovery as key drivers for returning the IP segment to growth [62][66] Question: Can you provide color on capital allocation priorities? - The company plans to focus on deleveraging this year while also considering stock buybacks, given the attractive free cash flow yield [69][70] Question: Can you speak to the composition of ACV and recurring revenue growth in 2025? - The company noted that improvements in ACV and recurring organic growth were primarily driven by volume rather than price realization [72][73]